Comparison of guanabenz and clonidine in hypertensive patients
- 1 January 1980
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 6 (9) , 638-643
- https://doi.org/10.1185/03007998009109502
Abstract
SummaryThe antihypertensive and clinical effects of two centrally acting drugs, guanabenz and clonidine, were compared in a double-blind trial in 29 patients with established hypertension. After a 1-week baseline period and 2 weeks on placebo, patients received treatment with either guanabenz (mean dose 24 mg daily) or clonidine (mean dose 0.45 mg daily) alone for 8 weeks. Both drugs produced equivalent and highly significant (p < 0.001) reductions in systolic and diastolic blood pressures in the standing and supine positions. They also reduced significantly the standing and supine pulse rates. Normal orthostatic responses were maintained with both regimens. AN but 1 patient in each group reported side-effects during active treatment, the most frequent being dry mouth and sedation with each drug. No laboratory or ECG abnormalities related to treatment were observed.Keywords
This publication has 5 references indexed in Scilit:
- Guanabenz and methyldopa on hypertension and cardiac performanceClinical Pharmacology & Therapeutics, 1977
- Guanabenz in essential hypertensionClinical Pharmacology & Therapeutics, 1977
- Guanabenz effects on blood pressure and noninvasive parameters of cardiac performance in patients with hypertensionClinical Pharmacology & Therapeutics, 1976
- Possible mechanism of the hypotensive action of 2,6-dichlorobenzylidene aminoguanidine: Evidence for central noradrenaline receptor stimulationEuropean Journal of Pharmacology, 1973
- 2,6-Dichlorobenzylidene amino guanidine acetate (Wy-8678). A new hypotensive agentCellular and Molecular Life Sciences, 1969